902
Views
98
CrossRef citations to date
0
Altmetric
Original Article

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast*

, , , , , & show all
Pages 1529-1538 | Accepted 21 Mar 2008, Published online: 16 Apr 2008

References

  • Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314–20
  • Anti-inflammatory activities of the novel PDE4 inhibitor CC-10004 against human leukocytes in vitro; Celgene Report Number 5042–107; July 1, 2004
  • Evaluation of anti-arthritic activity in the mAB/LPS-induced experimental murine arthritogenic model; Celgene Report Number CLG/002/EM; April 20, 2004
  • Gottlieb AB, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factoralpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003;48:68–75
  • Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002;46:886–91
  • Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti- CD11a antibody. Arch Dermatol 2002;138:591–600
  • Oestreicher JL, Walters IB, Kikuchi T, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001;1:272–87
  • Frederiksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978;157:238–44
  • Kruger J, Gottlieb A, Lebwohl M, et al. Safety, pharmacokinetics and histopathological effects of an oral P38 MAP kinase inhibitor (BIRB 796 BS), administered twice daily for 28 days in plaquetype psoriasis. The 9th International Psoriasis Symposium, New York, NY, June 17–22, 2003
  • Timmer W, Leclerc V, Birraux G, et al. The new phosphodiseterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-a ex vivo. J Clin Pharmacol 2002;42:297–303
  • Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842–7
  • Gottlieb AB. Tumor necrosis factor blockade: mechanism of action. J Investig Dermatol Symp Proc 2007;12:1–4
  • Numerof RP, Asadullah K. Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. BioDrugs 2006;20;93–103

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.